TKPHF - Takeda Pharmaceutical Company Limited

Other OTC - Other OTC Delayed Price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

Currency in JPY. All numbers in thousands
Breakdown
ttm
31/03/2023
31/03/2022
31/03/2021
31/03/2020
Total revenue
3,944,611,000
4,027,478,000
3,569,006,000
3,197,812,000
3,291,188,000
Cost of revenue
1,242,680,000
1,244,072,000
1,106,846,000
994,308,000
1,089,764,000
Gross profit
2,701,931,000
2,783,406,000
2,462,160,000
2,203,504,000
2,201,424,000
Operating expenses
Research development
616,009,000
633,325,000
526,087,000
455,833,000
492,381,000
Selling general and administrative
965,942,000
997,309,000
886,361,000
875,663,000
964,737,000
Total operating expenses
2,229,433,000
2,292,900,000
2,001,315,000
1,694,235,000
2,101,016,000
Operating income or loss
472,498,000
490,506,000
460,845,000
509,269,000
100,408,000
Interest expense
105,658,000
169,698,000
166,607,000
248,631,000
165,006,000
Total other income/expenses net
-102,686,000
-8,630,000
-15,367,000
76,000
-23,987,000
Income before tax
273,128,000
375,090,000
302,571,000
366,235,000
-60,754,000
Income tax expense
-1,399,000
58,052,000
72,405,000
-9,936,000
-105,044,000
Income from continuing operations
274,527,000
317,038,000
230,166,000
376,171,000
44,290,000
Net income
274,525,000
317,017,000
230,059,000
376,005,000
44,241,000
Net income available to common shareholders
274,525,000
317,017,000
230,059,000
376,005,000
44,241,000
Basic EPS
-
-
147.14
240.72
28.41
Diluted EPS
-
-
145.87
238.96
28.25
Basic average shares
-
-
1,563,501
1,562,006
1,557,204
Diluted average shares
-
-
1,577,169
1,573,537
1,566,204
EBITDA
-
1,209,188,000
1,052,329,000
1,174,537,000
687,901,000